BIO89-100-132 (Metabolic Dysfunction-Associated Steatohepatitis MASH)_Dinani - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called pegozafermin (the study drug) is a safe and effective option for people who have compensated liver cirrhosis due to MASH.

¿Cuál es la Condición que se está estudiando?

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

¿Quién puede participar en el Estudio?

Adults ages 18-75 who are diagnosed with compensated liver cirrhosis.

For more information, contact that study team at lauren.roberson@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment (like a coin flip) to either take the study drug or a placebo (inactive substance with no drug in it).

Regardless of your study assignment, you will:

Come to our clinic about 13 times over the course of 64 months
Realizar extracciones de sangre
Someterse a exámenes físicos
Fill out questionnaires

Detalles del Estudio

Título Completo

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigador Principal